AUROBINDO PHARMA LTD. - 524804 - Intimation Under Regulation 30 Of LODR - Disposal Of Business Assets Of Eugia US Manufacturing LLC, USA, A Wholly Owned Step- Down Subsidiary Of The Company
Intimation under Regulation 30 of LODR - Disposal of business assets of Eugia US Manufacturing LLC, USA, a wholly owned step-down subsidiary of the Company. AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At Unit III Of Eugia Pharma Specialities Ltd
Completion of US FDA inspection at Unit III of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company AUROBINDO PHARMA LTD. - 524804 - Board Meeting Intimation for Intimation Of Board Meeting For Consideration Of Unaudited Financial Results For The 3Rd Quarter & 9 Months Period Ended 31St December 2023.
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 ,inter alia, to consider and approve Intimation of Board meeting on Saturday, 10th February 2024 for consideration of unaudited standalone and consolidated financial results for the 3rd quarter and 9 month period ended on 31st December 2023. AUROBINDO PHARMA LTD. - 524804 - Clarification/Confirmation On News Item Appearing In Www.Cnbctv18.Com
Submission of clarification on news item appearing in www.cnbctv18.com AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate. AUROBINDO PHARMA LTD. - 524804 - Curateq Biologics Receives Recommendation For Grant Of Marketing Authorization Of 'Biosimilar Trastuzumab' From SEC Operating Under The Aegis Of CDSCO
CuraTeQ Biologics Private Limited, a wholly owned subsidiary company, received a recommendation for grant of marketing authorization of biosimilar Trastuzumab from SEC. AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of Confirmation.
Aurobindo Pharma gains on USFDA relief for Telangana unit
The share touched a 52-week high of Rs 1,133.95 on January 8, 2024 and a 52-week low of Rs 397.30 on February 3, 2023. AUROBINDO PHARMA LTD. - 524804 - Classification Of US FDA Inspection At Our Unit VI-B As VAII And Receipt Of EIR
Intimation of classification of USFDA Inspection at Unit VI-B of the Company as VAI and receipt of EIR AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates.